Pricey hepatitis C drugs threaten health care system

Photo: Eric Risberg, Associated Press A bipartisan investigation by U.S. senators finds that the makers...

When does Big Pharma profiting become profiteering? This issue was the subject last month of a Senate Finance Committee investigation of pricing practices of Gilead Sciences Inc., a leading provider of hepatitis C medications. After examining 20,000 pages of internal company documents, looking at Medicaid data and interviewing health care experts, the authors concluded that the Foster City drugmaker “pursued a calculated scheme for pricing and marketing its hepatitis C drug based on one goal: maximizing revenue regardless of the human consequences.” Community activists protested this kind of Big Pharma greed in front of the San Francisco hotel where the 34th annual J.P. Morgan Healthcare Conference opened Monday.